Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




May
12
Today In Oncology
First Virtual Cancer Clinic to Receive ASCO Certified Status
Meta-Analysis Explores Impact of Ovarian Function Suppression on Breast Cancer Recurrence and Survival
B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic GVHD
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo